The marketing authorisation for Alisade has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.
Alisade : EPAR - Summary for the public (PDF/236.73 KB)
First published: 11/06/2009
Last updated: 11/06/2009
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Glaxo Group Ltd.
|Date of issue of marketing authorisation valid throughout the European Union||
Glaxo Group Limited
Greenford, Middx UB6 0NN
17/02/2010 Alisade - EMEA/H/C/001019 - IB/0007
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Adults, adolescents (12 years and over) and children (6 - 11 years). Alisade is indicated for the treatment of the symptoms of allergic rhinitis.